Breaking News Instant updates and real-time market news.

IPSEY

Ipsen

, EXEL

Exelixis

$12.95

-0.23 (-1.75%)

05:26
10/10/16
10/10
05:26
10/10/16
05:26

Ipsen, Exelixis announces results from Phase 2 CABOSUN phase 2 trial

Ipsen (IPSEY) and its partner Exelixis (EXEL) announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma, or RCC, with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium, or IMDC. In CABOSUN, with a median follow-up of 20.8 months, cabozantinib demonstrated a clinically meaningful and statistically significant 31% reduction in the rate of disease progression or death. The median progression-free survival, or PFS, for cabozantinib was 8.2 months versus 5.6 months for sunitinib, corresponding to a 2.6 months improvement favoring cabozantinib over sunitinib. PFS benefits were independent of IMDC risk group and presence or absence of bone metastases at baseline. The results for sunitinib were in line with a previously published retrospective analysis of 1,174 intermediate- and poor-risk RCC patients from the IMDC database, which documented a median PFS of 5.6 months with a first-line targeted therapy, mainly sunitinib, in this patient population.

IPSEY

Ipsen

EXEL

Exelixis

$12.95

-0.23 (-1.75%)

  • 10

    Oct

  • 10

    Oct

IPSEY Ipsen

03/08/16
LEHM
03/08/16
DOWNGRADE
LEHM
Equal Weight
Ipsen downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Mark Purcell downgraded Ipsen to Equal Weight with a EUR 53 price target.
04/26/16
JEFF
04/26/16
UPGRADE
JEFF
Buy
Ipsen upgraded to Buy from Hold at Jefferies
05/09/16
MSCO
05/09/16
UPGRADE
MSCO
Overweight
Ipsen upgraded to Overweight from Equal Weight at Morgan Stanley
07/07/16
JPMS
07/07/16
DOWNGRADE
JPMS
Neutral
Ipsen downgraded to Neutral from Overweight at JPMorgan
EXEL Exelixis
$12.95

-0.23 (-1.75%)

08/04/16
STFL
08/04/16
NO CHANGE
STFL
Exelixis price target raised to $12 from $10 at Stifel
Stifel analyst Stephen Willey raised his price target on Exelixis after the company reported significantly better than expected Cabometyx and residual/off-label Cometriq sales into the newly launched indication of refractory renal cell carcinom. Willey expects the results to improve investors' confidence towards the company's growth outlook, and he says that anticipation of front-line CABOSUN results places a near-term floor on the stock. The analyst keeps a Buy rating on the shares.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Exelixis selloff overdone, says Leerink
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.

TODAY'S FREE FLY STORIES

SBGSY

Schneider Electric

$13.70

-0.115 (-0.83%)

15:24
02/24/17
02/24
15:24
02/24/17
15:24
Conference/Events
Schneider Electric management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 02

    Mar

SBGSY

Schneider Electric

$13.70

-0.115 (-0.83%)

15:23
02/24/17
02/24
15:23
02/24/17
15:23
Conference/Events
Schneider Electric management to meet with JPMorgan »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 02

    Mar

AVP

Avon Products

$4.43

0.18 (4.24%)

15:21
02/24/17
02/24
15:21
02/24/17
15:21
Hot Stocks
Avon Products rises after COO discloses purchase of 150K shares »

Avon Products COO James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

15:21
02/24/17
02/24
15:21
02/24/17
15:21
Options
Apple expiring ATM straddle is active as shares pin to $136 into the final hour »

Apple expiring ATM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

PPRUY

Kering

$24.38

0.055 (0.23%)

15:19
02/24/17
02/24
15:19
02/24/17
15:19
Conference/Events
Kering management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

$NSD

NASDAQ Market Internals

15:17
02/24/17
02/24
15:17
02/24/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/24/17
02/24
15:16
02/24/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$128.69

-1.04 (-0.80%)

15:14
02/24/17
02/24
15:14
02/24/17
15:14
Conference/Events
Aetna management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WMT

Wal-Mart

$72.37

1.055 (1.48%)

, BBY

Best Buy

$45.75

1.435 (3.24%)

15:12
02/24/17
02/24
15:12
02/24/17
15:12
Periodicals
White House denying Cohn comments on border-adjustment tax, Axios says »

The White House has…

WMT

Wal-Mart

$72.37

1.055 (1.48%)

BBY

Best Buy

$45.75

1.435 (3.24%)

COST

Costco

$175.85

-0.66 (-0.37%)

TGT

Target

$66.59

1.61 (2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

PYPL

PayPal

$42.53

0.11 (0.26%)

15:11
02/24/17
02/24
15:11
02/24/17
15:11
Options
$1M premium seller in Paypal »

$1M premium seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

  • 21

    Mar

  • 22

    Mar

  • 27

    Mar

  • 28

    Mar

WSTC

West Corp.

$24.66

-0.09 (-0.36%)

15:09
02/24/17
02/24
15:09
02/24/17
15:09
Conference/Events
West Corp. to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FCNCA

First Citizens

$363.85

0.03 (0.01%)

15:07
02/24/17
02/24
15:07
02/24/17
15:07
Hot Stocks
Breaking Hot Stocks news story on First Citizens »

Vanguard reports 5.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTR

Dollar Tree

$77.57

-0.97 (-1.24%)

15:06
02/24/17
02/24
15:06
02/24/17
15:06
Options
Dollar Tree call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

ADRO

Aduro Biotech

$11.15

-0.25 (-2.19%)

15:01
02/24/17
02/24
15:01
02/24/17
15:01
Hot Stocks
Meet Aduro: CEO Isaacs says partnerships help development efforts »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$1.42

-0.05 (-3.40%)

15:01
02/24/17
02/24
15:01
02/24/17
15:01
Hot Stocks
Breaking Hot Stocks news story on Sierra Oncology »

Frazier Healthcare VI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIGI

Endurance

$9.00

-0.3 (-3.23%)

14:59
02/24/17
02/24
14:59
02/24/17
14:59
Rumors
Rumor moving shares of Endurance »

Rumor: Endurance late day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WSTC

West Corp.

$24.66

-0.09 (-0.36%)

14:57
02/24/17
02/24
14:57
02/24/17
14:57
Periodicals
West Corp. buyout looks challenging, Dealreporter says »

Private equity firms have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

LUK

Leucadia

$25.63

-0.09 (-0.35%)

14:50
02/24/17
02/24
14:50
02/24/17
14:50
Options
Leucadia options imply 2.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWJ

iShares MSCI Japan Index Fund

$51.43

-0.205 (-0.40%)

14:41
02/24/17
02/24
14:41
02/24/17
14:41
Options
iShares Japan Fund draws a notable option block »

iShares Japan Fund draws…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RP

RealPage

$33.70

-0.5 (-1.46%)

14:36
02/24/17
02/24
14:36
02/24/17
14:36
Conference/Events
RealPage management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 02

    Mar

VLKAY

Volkswagen

$30.91

0.135 (0.44%)

14:29
02/24/17
02/24
14:29
02/24/17
14:29
Hot Stocks
Volkswagen took EUR6.4B in charges from diesel scandal in FY16 »

Volkswagen said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRO

Aduro Biotech

$11.15

-0.25 (-2.19%)

, NVS

Novartis

$77.15

-0.2959 (-0.38%)

14:27
02/24/17
02/24
14:27
02/24/17
14:27
Hot Stocks
Meet Aduro: Progress across 3 main platforms seen in 2017 »

In an exclusive interview…

ADRO

Aduro Biotech

$11.15

-0.25 (-2.19%)

NVS

Novartis

$77.15

-0.2959 (-0.38%)

JNJ

Johnson & Johnson

$122.09

1.19 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

  • 26

    Jun

SU

Suncor

$31.55

-1.12 (-3.43%)

14:26
02/24/17
02/24
14:26
02/24/17
14:26
Options
Suncor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$30.91

0.135 (0.44%)

14:21
02/24/17
02/24
14:21
02/24/17
14:21
Hot Stocks
Volkswagen sees FY17 operating return on sales 6%-7% »

The Volkswagen Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPKE

Spark Energy

$25.55

0.35 (1.39%)

14:21
02/24/17
02/24
14:21
02/24/17
14:21
Periodicals
Spark Energy hires Morgan Stanley to advise on potential sale, SparkSpread says »

Spark Energy has retained…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.